Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 506 of 5804
-
New pill HRS-7535 takes on diabetes in Head-to-Head trial
Disease control CompletedThe aim of this trial is to evaluate the efficacy and safety of HRS-7535 compared with dapagliflozin in subjects with type 2 diabetes mellitus with inadequate glycemic control using metformin.
Phase: PHASE3 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo aims for deeper remission in older leukemia patients
Disease control Recruiting nowThis phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New blood filter aims to save lives in liver failure and sepsis
Disease control Recruiting nowThis study aims to evaluate the efficacy and safety of the double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE) in patients with acute-on-chronic liver failure (ACLF) complicated by sepsis. The focus is on assessing the impact of the cytok…
Phase: NA • Sponsor: Third Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug duo targets Hard-to-Treat head and neck cancer
Disease control Recruiting nowThis phase II study will be conducted in two parts (Ⅱa and Ⅱb), with a 21-day treatment cycle until disease progression, intolerable toxicity, withdrawal of informed consent, death, initiation of new anti-tumor treatment or loss of follow-up.
Phase: PHASE2 • Sponsor: Shanghai Institute Of Biological Products • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Simple blood test aims to catch cancers early in genetically prone patients
Diagnosis Recruiting nowThe purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early. The name of the screening blood test being studied is: -GRAIL Galleri test
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
Glowing dye could help surgeons spot hidden cancer during colorectal surgery
Disease control ENROLLING_BY_INVITATIONPrevious studies of Indocyanine green (ICG) in colorectal surgery have focused on lymphatic mapping, lymph node detection, and the number of harvested lymph nodes. However, relatively few studies have evaluated the outcomes of this imaging technology, especially the prognosis fol…
Phase: NA • Sponsor: Shanghai Tong Ren Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Hard-to-Treat breast cancer: targeted pill plus hormone therapy shows promise
Disease control OngoingThis is a multi-center, two-cohorts, phase IIIb study of Capivasertib+Fulvestrant in HR+/HER2-ABC who had disease recurrence/progression following 1-2L endocrine therapy. The Primary objective is to assess the efficacy of capi+ful by assessment of TFST (Time to first subsequent …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cancer-Fighting virus plus chemo and immunotherapy takes on lung cancer in new trial
Disease control Recruiting nowThis Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint I…
Phase: PHASE2 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Stroke drug dosing trial aims to improve recovery for thousands
Disease control Recruiting nowThis domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design. Up to 4,000 patients with presumed acute ischemic stroke (AIS) will be followed for 90 days (or until death, if prior to 90 days). The end of the tri…
Phase: PHASE3 • Sponsor: University of Calgary • Aim: Disease control
Last updated Jun 26, 2026 18:47 UTC
-
Could a Double-Dose flu vaccine better protect transplant kids?
⭐️ VACCINE ⭐️ Recruiting nowInfluenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcome poor immune responses i…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
Experimental CAR T-Cell therapy targets rare stiff person syndrome
Disease control CompletedA Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome
Phase: PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for tough ovarian cancer: CBX-12 trial launches
Disease control Recruiting nowThe purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Phase: PHASE2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for dravet syndrome: phase 3 trial of LP352 aims to cut seizure frequency
Disease control Recruiting nowThis (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period,…
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Virus therapy takes on hard-to-treat ovarian cancer
Disease control Recruiting nowA research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumo…
Phase: PHASE1, PHASE2 • Sponsor: Theolytics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo aims to stop lung Cancer's return
Disease control OngoingThe purpose of this Phase II, open-label, multicentre, single-arm study is to assess efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) in participants with locally advanced (Stage III), unresectable non-small cell lung cancer (NSCLC), who have …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Lymphedema prevention trial: a new hope for breast cancer patients
Prevention Recruiting nowTo learn if reconstruction of the lymphatic system at the time of axillary lymphadenectomy can reduce the risk of developing lymphedema.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC
-
New device aims to seal off stroke risk without blood thinners
Disease control OngoingThe CLAAS® device will be evaluated for safety and performance in the reduction of stroke in subjects with non-valvular atrial fibrillation under intracardiac echocardiography (ICE) imaging for left atrial appendage closure.
Phase: NA • Sponsor: Conformal Medical, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo approach aims to boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy targets both joint pain and obesity in PsA patients
Disease control CompletedThe main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement i…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a diabetes drug help heart muscle disease? large trial underway
Symptom relief Recruiting nowThe main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compared to placebo.
Phase: PHASE3 • Sponsor: Lexicon Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC